StockMacro
Menu

ResMed

$235.63 +13% in 6 monthsMarket cap $33.1B

RMD on XNYS, Health Care, ResMed Inc., job postings

Measures activity, not value. Not investment advice.

Profit rose 11% to $1.6B in 12 months, but the shares fell 3.4% over the same span.

  • GoodForeign specialist hiring applications up 94% to 31 in 12 months
  • GoodLatest quarter revenue up 5.9% to $1.4B

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
11,370
Website
resmed.com
Listed
NYSE, US
Last results
29 Oct 2026
Next results
expected around 28 Jan 2027 (an estimate: a year ago it reported on 29 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.4B, net income $418.4M.
Quarter to 31 Dec 2021: revenue $919.3M, net income $201.8MQuarter to 31 Dec 2021: revenue $919.3M, net income $201.8MQuarter to 31 Mar 2022: revenue $884.3M, net income $179.0MQuarter to 31 Mar 2022: revenue $884.3M, net income $179.0MQuarter to 30 Jun 2022: revenue $935.4M, net income $195.1MQuarter to 30 Jun 2022: revenue $935.4M, net income $195.1MQuarter to 30 Sep 2022: revenue $974.0M, net income $210.5MQuarter to 30 Sep 2022: revenue $974.0M, net income $210.5MQuarter to 31 Dec 2022: revenue $1.1B, net income $224.9MQuarter to 31 Dec 2022: revenue $1.1B, net income $224.9MQuarter to 31 Mar 2023: revenue $1.1B, net income $232.5MQuarter to 31 Mar 2023: revenue $1.1B, net income $232.5MQuarter to 30 Jun 2023: revenue –, net income $229.7MQuarter to 30 Sep 2023: revenue $1.1B, net income $219.4MQuarter to 30 Sep 2023: revenue $1.1B, net income $219.4MQuarter to 31 Dec 2023: revenue $1.2B, net income $208.8MQuarter to 31 Dec 2023: revenue $1.2B, net income $208.8MQuarter to 31 Mar 2024: revenue $1.2B, net income $300.5MQuarter to 31 Mar 2024: revenue $1.2B, net income $300.5MQuarter to 30 Jun 2024: revenue –, net income $292.2MQuarter to 30 Sep 2024: revenue $1.2B, net income $311.4MQuarter to 30 Sep 2024: revenue $1.2B, net income $311.4MQuarter to 31 Dec 2024: revenue $1.3B, net income $344.6MQuarter to 31 Dec 2024: revenue $1.3B, net income $344.6MQuarter to 31 Mar 2025: revenue $1.3B, net income $365.0MQuarter to 31 Mar 2025: revenue $1.3B, net income $365.0MQuarter to 30 Jun 2025: revenue –, net income $379.7MQuarter to 30 Sep 2025: revenue $1.4B, net income $348.5MQuarter to 30 Sep 2025: revenue $1.4B, net income $348.5MQuarter to 31 Dec 2025: revenue $1.4B, net income $392.6MQuarter to 31 Dec 2025: revenue $1.4B, net income $392.6MQuarter to 31 Mar 2026: revenue $1.5B, net income $398.7MQuarter to 31 Mar 2026: revenue $1.5B, net income $398.7MQuarter to 30 Jun 2026: revenue –, net income $383.4MQuarter to 30 Sep 2026: revenue $1.4B, net income $418.4MQuarter to 30 Sep 2026: revenue $1.4B, net income $418.4M
31 Dec 2021RevenueNet incometallest bar $1.5B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.4B$418.4M
30 Jun 2026–$383.4M
31 Mar 2026$1.5B$398.7M
31 Dec 2025$1.4B$392.6M
30 Sep 2025$1.4B$348.5M
30 Jun 2025–$379.7M
31 Mar 2025$1.3B$365.0M
31 Dec 2024$1.3B$344.6M
30 Sep 2024$1.2B$311.4M
30 Jun 2024–$292.2M
31 Mar 2024$1.2B$300.5M
31 Dec 2023$1.2B$208.8M
30 Sep 2023$1.1B$219.4M
30 Jun 2023–$229.7M
31 Mar 2023$1.1B$232.5M
31 Dec 2022$1.1B$224.9M
30 Sep 2022$974.0M$210.5M
30 Jun 2022$935.4M$195.1M
31 Mar 2022$884.3M$179.0M
31 Dec 2021$919.3M$201.8M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $5.7B $5.3B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +9.0% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $1.6B $1.4B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $10.98 $9.77
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 61.1% 60.0% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 33.0% 33.2% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 27.8% 27.3% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 26.4% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $1.6B $1.8B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $1.0B $1.4B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $409.6M $668.6M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$601.1M (net cash) -$715.3M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.07 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $42.29
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 20.8 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 5.8 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 5.7 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.6 2.8
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 1.0% 1.4%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ResMedRMD (this company) $33.1B20.85.8+9.0%27.8%
MedlineMDLN $32.5B36.61.1–2.9%
DexComDXCM $29.6B29.95.8+13%19.4%
West Pharmaceutical ServicesWST $27.2B42.68.0+13%18.8%
Becton, Dickinson andBDX $58.0B61.62.8+5.2%4.5%
Boston ScientificBSX $60.8B17.42.9+8.9%16.6%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$3.8M

bought $0, sold $3.8M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+1.0%

873 13F filers vs 864

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

66%

92.4M shares held by 13F filers (30 Sep 2026) of 140.7M outstanding (26 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

7.4%

10.5M shares sold short (30 Oct 2026) of 140.7M outstanding (26 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.0

10.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-12%

11.9M shares sold short in the report before, 10.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

89%

89% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 73%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+94%

31 vs 16 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+5.9%

$1.4B vs $1.4B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+13%

$48.7M vs $43.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$550K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

53

53 articles in the last 7 days; its usual week has 7.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

7.1×

53 articles in the last 7 days; its usual week has 7.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Lobbying spend $130K, 2.2× a year earlier

Price $235.63 on 20 Nov 2026, -3.4% over 12 months (12-month range $182.82 to $275.96)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $19.7M in the last 12 months (the 12 months before: -$37.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 31 published in the last 12 months, +94% on the 12 months before.
Revenue per quarter. Revenue $1.4B in the latest quarter, +5.9% on a year earlier.
Capital spending per quarter. Capital spending $48.7M in the latest quarter, +13% on a year earlier.
Institutional holders (13F filers). 873 13F filers reported holding it in the latest 13F quarter, -2.9% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.
Lobbying spend. Lobbying spend: $550K published in the last 12 months, +129% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
19 Nov 20268-K and other filingsDirector Ronald Taylor did not seek re-election; term ended at Nov 18, 2026 annual meeting; board cut to ten
19 Nov 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2026Sharp changeLobbying spend jump: lobbying spend jump, 130K vs usual 60K (2026-09-30); 2.2x the same period a year earlier
18 Aug 2026Lobbying filingnew lobbying registration (TAFT STETTINIUS & HOLLISTER LLP DBA TAFT ADVISORS LLC FKA (TAFT, STETTINIUS & HO)
17 Aug 20268-K and other filingsChanged its auditor
17 Aug 20268-K and other filingsDirector or officer change
17 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jul 2026Sharp changeLobbying spend jump: lobbying spend jump, 140K vs usual 60K (2026-06-30); 2.3x the same period a year earlier
9 Jul 2026Lobbying filinglobbying engagement terminated (ICE MILLER LLP)
30 Apr 20268-K and other filingsDirector or officer change
30 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jan 2026Sharp changeLobbying spend jump: lobbying spend jump, 130K vs usual 60K (2025-12-31); 2.2x the same period a year earlier
20 Jan 2026Sharp changeLobbying on a new issue: lobbying on a new issue: TAR (2025-12-31)
20 Nov 20258-K and other filingsDirector or officer change
20 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Nov 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 43.0M vs usual 22.3M (2025-09-30); 2.4x the same period a year earlier
20 Oct 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MAN, MED, VET (2025-09-30)
16 Oct 2025Lobbying filinglobbying engagement terminated (DLA PIPER LLP (US))
3 Oct 2025Lobbying filingnew lobbying registration (ICE MILLER LLP)
18 Aug 20258-K and other filingsDirector or officer change
31 Jul 20258-K and other filingsDirector or officer change
31 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Aug 20248-K and other filingsDirector or officer change
16 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Mar 2024Sharp changeShort interest spike: short interest spike, 6.6M vs usual 1.5M (2024-02-15); 6.2x the same period a year earlier
13 Feb 2024Sharp changeShort interest spike: short interest spike, 6.3M vs usual 1.4M (2024-01-31); 7.5x the same period a year earlier
30 Jan 2024Sharp changeShort interest spike: short interest spike, 5.9M vs usual 1.4M (2024-01-12); 6.9x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 5.7M vs usual 1.3M (2023-12-29); 5.6x the same period a year earlier
2 Jan 2024Sharp changeShort interest spike: short interest spike, 5.8M vs usual 1.3M (2023-12-15); 6.1x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 5.9M vs usual 1.2M (2023-11-30); 5.8x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 6.3M vs usual 1.2M (2023-11-15); 5.9x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 5.7M vs usual 1.2M (2023-10-31); 4.4x the same period a year earlier
9 Nov 20238-K and other filingsDirector or officer change
9 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Oct 2023Sharp changeShort interest spike: short interest spike, 4.8M vs usual 1.2M (2023-10-13); 3.9x the same period a year earlier
17 Oct 2023Sharp changeShort interest spike: short interest spike, 4.8M vs usual 1.2M (2023-09-29); 3.5x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 3.8M vs usual 1.2M (2023-09-15); 2.5x the same period a year earlier
19 Sep 2023Sharp changeShort interest spike: short interest spike, 3.2M vs usual 1.2M (2023-08-31); 2.5x the same period a year earlier
30 Mar 20238-K and other filingsDirector or officer change
26 Jan 20238-K and other filingsDirector or officer change
26 Jan 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Aug 2022Sharp changeLobbying spend jump: lobbying spend jump, 180K vs usual 45K (2022-06-30); 4.5x the same period a year earlier
2 Aug 2022Sharp changeLobbying spend jump: lobbying spend jump, 210K vs usual 40K (2022-03-31); 5.2x the same period a year earlier
27 Jul 2022Lobbying filingnew lobbying registration (DLA PIPER LLP (US))
1 Jul 20228-K and other filingsDirector or officer change
11 May 20228-K and other filingsDirector or officer change
11 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 May 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 48.4M vs usual 27.6M (2022-03-31); 1.8x the same period a year earlier
Insider net buying (open market)
Month from 1 Nov 2021: -$390K published
Month from 1 Dec 2021: -$5.2M published
Month from 1 Jan 2022: -$4.3M published
Month from 1 Feb 2022: -$4.2M published
Month from 1 Mar 2022: -$4.3M published
Month from 1 Apr 2022: -$4.2M published
Month from 1 May 2022: -$1.4M published
Month from 1 Jun 2022: -$1.5M published
Month from 1 Jul 2022: -$3.4M published
Month from 1 Aug 2022: -$2.3M published
Month from 1 Sep 2022: -$5.6M published
Month from 1 Oct 2022: -$4.0M published
Month from 1 Nov 2022: -$9.0M published
Month from 1 Dec 2022: -$1.6M published
Month from 1 Jan 2023: -$1.9M published
Month from 1 Feb 2023: -$5.0M published
Month from 1 Mar 2023: -$2.0M published
Month from 1 Apr 2023: -$2.5M published
Month from 1 May 2023: -$5.9M published
Month from 1 Jun 2023: -$2.0M published
Month from 1 Jul 2023: -$1.7M published
Month from 1 Aug 2023: -$1.3M published
Month from 1 Sep 2023: -$835K published
Month from 1 Oct 2023: -$802K published
Month from 1 Nov 2023: -$1.3M published
Month from 1 Feb 2024: -$5.0M published
Month from 1 Mar 2024: -$49K published
Month from 1 May 2024: -$6.1M published
Month from 1 Jun 2024: -$3.3M published
Month from 1 Jul 2024: -$3.0M published
Month from 1 Aug 2024: -$16.1M published
Month from 1 Sep 2024: -$5.6M published
Month from 1 Oct 2024: -$5.1M published
Month from 1 Nov 2024: -$6.6M published
Month from 1 Dec 2024: -$754K published
Month from 1 Jan 2025: -$713K published
Month from 1 Feb 2025: -$2.6M published
Month from 1 Mar 2025: -$7.0M published
Month from 1 Apr 2025: -$2.4M published
Month from 1 May 2025: -$3.8M published
Month from 1 Jun 2025: -$2.8M published
Month from 1 Jul 2025: -$3.3M published
Month from 1 Aug 2025: -$3.8M published
Month from 1 Sep 2025: -$3.0M published
Month from 1 Oct 2025: -$3.1M published
Month from 1 Nov 2025: -$3.9M published
Month from 1 Dec 2025: -$2.0M published
Month from 1 Jan 2026: -$2.0M published
Month from 1 Feb 2026: -$2.1M published
Month from 1 Mar 2026: -$2.0M published
Month from 1 Apr 2026: -$1.8M published
Month from 1 May 2026: -$1.0M published
Month from 1 Jun 2026: -$968K published
Month from 1 Jul 2026: -$1.1M published
Month from 1 Aug 2026: -$2.8M published
Month from 1 Sep 2026: -$1.3M published
Month from 1 Oct 2026: -$1.2M published
Month from 1 Nov 2026: -$1.3M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 5 published
Quarter from 1 Apr 2022: 2 published
Quarter from 1 Jul 2022: 7 published
Quarter from 1 Oct 2022: 2 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 5 published
Quarter from 1 Oct 2023: 5 published
Quarter from 1 Jan 2024: 7 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 4 published
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Jan 2025: 3 published
Quarter from 1 Jul 2025: 11 published
Quarter from 1 Oct 2025: 2 published
Quarter from 1 Jan 2026: 2 published
Quarter from 1 Apr 2026: 2 published
Quarter from 1 Jul 2026: 7 published
Quarter from 1 Oct 2026: 20 published
Revenue per quarter
Quarter ended 31 Dec 2021: $919.3M, +11% on a year earlier; public on 29 Jan 2022
Quarter ended 31 Mar 2022: $884.3M, +12% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $935.4M, +4.3% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $974.0M, +4.8% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $1.1B, +15% on a year earlier; public on 28 Jan 2023
Quarter ended 31 Mar 2023: $1.1B, +29% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Sep 2023: $1.1B, +16% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $1.2B, +12% on a year earlier; public on 26 Jan 2024
Quarter ended 31 Mar 2024: $1.2B, +7.2% on a year earlier; public on 27 Apr 2024
Quarter ended 30 Sep 2024: $1.2B, +11% on a year earlier; public on 26 Oct 2024
Quarter ended 31 Dec 2024: $1.3B, +10% on a year earlier; public on 1 Feb 2025
Quarter ended 31 Mar 2025: $1.3B, +7.8% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Sep 2025: $1.4B, +9.0% on a year earlier; public on 1 Nov 2025
Quarter ended 31 Dec 2025: $1.4B, +11% on a year earlier; public on 31 Jan 2026
Quarter ended 31 Mar 2026: $1.5B, +11% on a year earlier; public on 2 May 2026
Quarter ended 30 Sep 2026: $1.4B, +5.9% on a year earlier; public on 31 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $30.4M, -13% on a year earlier; public on 29 Jan 2022
Quarter ended 31 Mar 2022: $48.4M, +84% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $28.6M, +2.6% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $29.1M, +6.3% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $27.4M, -10% on a year earlier; public on 28 Jan 2023
Quarter ended 31 Mar 2023: $28.8M, -41% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $34.4M, +20% on a year earlier; public on 12 Aug 2023
Quarter ended 30 Sep 2023: $30.0M, +3.4% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $23.4M, -15% on a year earlier; public on 26 Jan 2024
Quarter ended 31 Mar 2024: $21.2M, -26% on a year earlier; public on 27 Apr 2024
Quarter ended 30 Jun 2024: $24.9M, -28% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $17.8M, -41% on a year earlier; public on 26 Oct 2024
Quarter ended 31 Dec 2024: $20.6M, -12% on a year earlier; public on 1 Feb 2025
Quarter ended 31 Mar 2025: $20.8M, -1.9% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Jun 2025: $30.6M, +23% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $43.0M, +141% on a year earlier; public on 1 Nov 2025
Quarter ended 31 Dec 2025: $28.5M, +38% on a year earlier; public on 31 Jan 2026
Quarter ended 31 Mar 2026: $33.7M, +62% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $51.1M, +67% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $48.7M, +13% on a year earlier; public on 31 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 637; public on 14 Feb 2022
31 Mar 2022 report: 637; public on 16 May 2022
30 Jun 2022 report: 629; public on 15 Aug 2022
30 Sep 2022 report: 599; public on 14 Nov 2022
31 Dec 2022 report: 652; public on 14 Feb 2023
31 Mar 2023 report: 628; public on 15 May 2023
30 Jun 2023 report: 666; public on 14 Aug 2023
30 Sep 2023 report: 602; public on 14 Nov 2023
31 Dec 2023 report: 642; public on 14 Feb 2024
31 Mar 2024 report: 681; public on 15 May 2024
30 Jun 2024 report: 723; public on 14 Aug 2024
30 Sep 2024 report: 740; public on 14 Nov 2024
31 Dec 2024 report: 824; public on 14 Feb 2025
31 Mar 2025 report: 838; public on 15 May 2025
30 Jun 2025 report: 875; public on 14 Aug 2025
30 Sep 2025 report: 899; public on 14 Nov 2025
31 Dec 2025 report: 906; public on 17 Feb 2026
31 Mar 2026 report: 916; public on 15 May 2026
30 Jun 2026 report: 864; public on 14 Aug 2026
30 Sep 2026 report: 873; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2022: -$62K published
Lobbying spend
Quarter from 1 Jul 2022: $610K published
Quarter from 1 Oct 2022: $70K published
Quarter from 1 Jan 2023: $50K published
Quarter from 1 Apr 2023: $50K published
Quarter from 1 Jul 2023: $40K published
Quarter from 1 Oct 2023: $40K published
Quarter from 1 Jan 2024: $40K published
Quarter from 1 Apr 2024: $50K published
Quarter from 1 Jul 2024: $40K published
Quarter from 1 Oct 2024: $60K published
Quarter from 1 Jan 2025: $60K published
Quarter from 1 Apr 2025: $60K published
Quarter from 1 Jul 2025: $60K published
Quarter from 1 Oct 2025: $60K published
Quarter from 1 Jan 2026: $130K published
Quarter from 1 Apr 2026: $150K published
Quarter from 1 Jul 2026: $140K published
Quarter from 1 Oct 2026: $130K published

What is unusual now

  • Made public in the last 90 days: it reported $130K of lobbying spend for the quarter ended 30 Sep 2026, 2.2× the same quarter last year.
  • Lobbying spend jump: reported $140K of lobbying spend for the quarter ended 30 Jun 2026, 2.3× the same quarter last year Public on 20 Jul 2026.
  • Insider net buying (open market): Insiders sold a net $19.7M in the last 12 months (the 12 months before: -$37.2M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 31 published in the last 12 months, +94% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 6 sales, $3.8M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Jan De WitteDirectorSellplanned in advance (10b5-1)429$237.00$102KForm 4
12 Nov 2026Michael J. FarrellChairman and CEOSellplanned in advance (10b5-1); after exercising options4,993$235.35$1.2MForm 4
26 Oct 2026Michael J RiderGlobal General CounselSellplanned in advance (10b5-1)400$255.00$102KForm 4
8 Oct 2026Michael J. FarrellChairman and CEOSellplanned in advance (10b5-1); after exercising options4,991$226.33$1.1MForm 4
10 Sep 2026Michael J. FarrellChairman and CEOSellplanned in advance (10b5-1); after exercising options4,991$222.44$1.1MForm 4
4 Sep 2026Peter C FarrellDirectorSellplanned in advance (10b5-1)970$234.73$228KForm 4
11 Aug 2026Michael J. FarrellChairman and CEOSellplanned in advance (10b5-1); after exercising options4,991$205.69$1.0MForm 4
6 Aug 2026Peter C FarrellDirectorSellplanned in advance (10b5-1)8,000$225.00$1.8MForm 4

873 institutions reported shares at the end of Q3 2026, 66% of the shares outstanding; 100 opened a position, 98 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.12.0M8.50%$2.6B-363K-2.9%
Vanguard Capital Management LLC9.4M6.72%$2.1B-28K-0.3%
Vanguard Portfolio Management LLC7.9M5.63%$1.8B+10K+0.1%
State Street Corp6.5M4.63%$1.4B-161K-2.4%
Geode Capital Management, LLC4.4M3.14%$973.9M+68K+1.6%
Bank of New York Mellon Corp3.7M2.65%$824.5M-468K-11%
First Trust Advisors LP2.7M1.91%$594.5M+410K+18%
Morgan Stanley1.9M1.36%$422.6M-18K-0.9%
Invesco Ltd.1.7M1.20%$374.6M-369K-18%
Northern Trust Corp1.5M1.05%$325.2M-226K-13%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 31 Mar 2020. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
31 Mar 2020Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$32.0Mup to $33.0MVENTILATORS ARE PURCHASE TO SUPPORT COVID-19USAspending

Company events

All 26 company events

In 12 months: 3 director or officer changes, 1 auditor change. Results releases and routine reports are left out.

FiledWhat happenedSource
19 Nov 2026Director Ronald Taylor did not seek re-election; term ended at Nov 18, 2026 annual meeting; board cut to tenSame filing: shareholder vote results8-K
17 Aug 2026Director or officer change; Changed its auditor8-K
30 Apr 2026Director or officer change8-K
20 Nov 2025Director or officer changeSame filing: shareholder vote results8-K
18 Aug 2025Director or officer change8-K
31 Jul 2025Director or officer change8-K
16 Aug 2024Director or officer change8-K
9 Nov 2023Director or officer change8-K

Reported lobbying spend: $130K in Q3 2026, $140K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Aug 2026NewTaft Stettinius & Hollister LLP Dba Taft Advisors LLC Fka (Taft, Stettinius & Hofor Resmed Corp.Issues pertaining to medical devices and supply chain management.Health issues, Manufacturing, MED, VETFiling
30 Jun 2026EndedIce Miller LLPfor Resmed Corp.Issues related to ResMed.Manufacturing, MED, VET, Health issuesFiling
30 Sep 2025NewIce Miller LLPfor Resmed Corp.Issues related to ResMed Corp.Manufacturing, MED, VET, Health issuesFiling
31 Aug 2025EndedDla Piper LLP (US)for Resmed Corp.Issues related to medical devices and healthcare policy. Supply chain issues.Health issuesFiling
30 Nov 2021NewDla Piper LLP (US)for Resmed Corp.Efforts to address product shortages in medical devices and supply chain issues.Health issuesFiling
31 Dec 2019EndedBaker Donelson Bearman Caldwell & Berkowitzfor Resmed Corp.Not statedFiling
1 May 2017NewBaker Donelson Bearman Caldwell & Berkowitzfor Resmed Corp.Competitive biddingMedicare/MedicaidFiling
23 Mar 2016NewAkin Gump Strauss Hauer & Feldfor Resmed Corp.FDA reform legislation; telemonitoring; competitive bidding.Health issuesFiling

The 5 newest of 403 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

4 Nov 2025confirmed

Confirmed across sources Filings + Financials and Lobbying

ResMed (RMD): lobbying on a new issue, while it spent $43.0M on capital projects in the quarter ended 30 Sep 2025, 2.4× the same quarter last year. Two unrelated kinds of activity within 15 days.

  • Lobbying: Lobbying on a new issue, became public on 20 Oct 2025
  • Financials: Quarterly capital spending jump, became public on 4 Nov 2025
2023-09-30: $30.0M2023-12-31: $23.4M2024-03-31: $21.2M2024-06-30: $24.9M2024-09-30: $17.8M2024-12-31: $20.6M2025-03-31: $20.8M2025-06-30: $30.6M2025-09-30: $43.0M
The quarter ended 30 Sep 2025 against the 8 quarters before it. this quarterearliernormal: $22.3M
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 20 Oct 2025

ResMed lobbying on a new issue.

New
['MAN', 'MED', 'VET']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4691494

Financials: Quarterly capital spending jump became public on 4 Nov 2025

ResMed spent $43.0M on capital projects in the quarter ended 30 Sep 2025, 2.4× the same quarter last year.

This period
$43.0M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$22.3M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+6.6
Same quarter last year
$17.8M
History used
5,844 days
2023-09-30: $30.0M2023-12-31: $23.4M2024-03-31: $21.2M2024-06-30: $24.9M2024-09-30: $17.8M2024-12-31: $20.6M2025-03-31: $20.8M2025-06-30: $30.6M2025-09-30: $43.0M
the quarter ended 30 Sep 20258 earlier quartersnormal: $22.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Nov 2026Filings change

    filed a director or officer change: Director Ronald Taylor did not seek re-election; term ended at Nov 18, 2026 annual meeting; board cut to ten.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 19 Nov 2026Filings record

    Director Ronald Taylor did not seek re-election; term ended at Nov 18, 2026 annual meeting; board cut to ten

  3. 20 Oct 2026Lobbying change

    reported $130K of lobbying spend for the quarter ended 30 Sep 2026, 2.2× the same quarter last year.

    Same quarter last year: $60K; its normal quarter is $60K.

    See the evidence
    This period
    $130K (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $60K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +3.5
    Same quarter last year
    $60K
    History used
    6,666 days
    2024-09-30: $60K2024-12-31: $60K2025-03-31: $60K2025-06-30: $60K2025-09-30: $60K2025-12-31: $130K2026-03-31: $150K2026-06-30: $140K2026-09-30: $130K
    the quarter ended 30 Sep 20268 earlier quartersnormal: $60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  4. 18 Aug 2026Lobbying record

    RESMED CORP.: new lobbying registration (TAFT STETTINIUS & HOLLISTER LLP DBA TAFT ADVISORS LLC FKA (TAFT, STETTINIUS & HO) (dated 1 Aug 2026)

  5. 17 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 17 Aug 2026Filings record

    Director or officer change

  7. 17 Aug 2026Filings record

    Changed its auditor

  8. 20 Jul 2026Lobbying change

    reported $140K of lobbying spend for the quarter ended 30 Jun 2026, 2.3× the same quarter last year.

    Same quarter last year: $60K; its normal quarter is $60K.

    See the evidence
    This period
    $140K (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $60K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +4.0
    Same quarter last year
    $60K
    History used
    6,574 days
    2024-06-30: $40K2024-09-30: $60K2024-12-31: $60K2025-03-31: $60K2025-06-30: $60K2025-09-30: $60K2025-12-31: $130K2026-03-31: $150K2026-06-30: $140K
    the quarter ended 30 Jun 20268 earlier quartersnormal: $60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  9. 9 Jul 2026Lobbying record

    RESMED CORP.: lobbying engagement terminated (ICE MILLER LLP) (dated 30 Jun 2026)

  10. 30 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 30 Apr 2026Filings record

    Director or officer change

  12. 20 Jan 2026Lobbying change

    reported $130K of lobbying spend for the quarter ended 31 Dec 2025, 2.2× the same quarter last year.

    Same quarter last year: $60K; its normal quarter is $60K.

    See the evidence
    This period
    $130K (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $60K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +3.5
    Same quarter last year
    $60K
    History used
    6,301 days
    2023-12-31: $40K2024-03-31: $50K2024-06-30: $40K2024-09-30: $60K2024-12-31: $60K2025-03-31: $60K2025-06-30: $60K2025-09-30: $60K2025-12-31: $130K
    the quarter ended 31 Dec 20258 earlier quartersnormal: $60K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  13. 20 Jan 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['TAR']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4689302
  14. 20 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 20 Nov 2025Filings record

    Director or officer change

  16. 4 Nov 2025several at once

    lobbying on a new issue, while it spent $43.0M on capital projects in the quarter ended 30 Sep 2025, 2.4× the same quarter last year. Two unrelated kinds of activity within 15 days.

    See the evidence (2 changes)

    Lobbying: Lobbying on a new issue became public on 20 Oct 2025

    ResMed lobbying on a new issue.

    New
    ['MAN', 'MED', 'VET']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4691494

    Financials: Quarterly capital spending jump became public on 4 Nov 2025

    ResMed spent $43.0M on capital projects in the quarter ended 30 Sep 2025, 2.4× the same quarter last year.

    This period
    $43.0M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $22.3M
    Typical spread (median absolute deviation)
    $2.1M
    How far from its usual level
    +6.6
    Same quarter last year
    $17.8M
    History used
    5,844 days
    2023-09-30: $30.0M2023-12-31: $23.4M2024-03-31: $21.2M2024-06-30: $24.9M2024-09-30: $17.8M2024-12-31: $20.6M2025-03-31: $20.8M2025-06-30: $30.6M2025-09-30: $43.0M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $22.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  17. 4 Nov 2025Financials change

    spent $43.0M on capital projects in the quarter ended 30 Sep 2025, 2.4× the same quarter last year.

    Same quarter last year: $17.8M; its normal quarter is $22.3M.

    See the evidence
    This period
    $43.0M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $22.3M
    Typical spread (median absolute deviation)
    $2.1M
    How far from its usual level
    +6.6
    Same quarter last year
    $17.8M
    History used
    5,844 days
    2023-09-30: $30.0M2023-12-31: $23.4M2024-03-31: $21.2M2024-06-30: $24.9M2024-09-30: $17.8M2024-12-31: $20.6M2025-03-31: $20.8M2025-06-30: $30.6M2025-09-30: $43.0M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $22.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 20 Oct 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MAN', 'MED', 'VET']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4691494
  19. 16 Oct 2025Lobbying record

    RESMED CORP.: lobbying engagement terminated (DLA PIPER LLP (US)) (dated 31 Aug 2025)

  20. 3 Oct 2025Lobbying record

    RESMED CORP.: new lobbying registration (ICE MILLER LLP) (dated 30 Sep 2025)

  21. 18 Aug 2025Filings record

    Director or officer change

  22. 31 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  23. 31 Jul 2025Filings record

    Director or officer change

  24. 16 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  25. 16 Aug 2024Filings record

    Director or officer change

  26. 28 Feb 2024Short interest and volume change

    had 6.6M shares sold short in the 15 Feb 2024 report, 6.2× the same report last year.

    Same report last year: 1.1M; its normal report is 1.5M.

    See the evidence
    This period
    6.6M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    448K
    How far from its usual level
    +7.7
    Same report last year
    1.1M
    History used
    2,239 days
    2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M2023-10-31: 5.7M2023-11-15: 6.3M2023-11-30: 5.9M2023-12-15: 5.8M2023-12-29: 5.7M2024-01-12: 5.9M2024-01-31: 6.3M2024-02-15: 6.6M
    the 15 Feb 2024 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 10 Feb 2024Short interest and volume change

    had 6.3M shares sold short in the 31 Jan 2024 report, 7.5× the same report last year.

    Same report last year: 845K; its normal report is 1.4M.

    See the evidence
    This period
    6.3M (the 31 Jan 2024 report)
    Normal report (median of 24 earlier)
    1.4M
    Typical spread (median absolute deviation)
    410K
    How far from its usual level
    +8.1
    Same report last year
    845K
    History used
    2,224 days
    2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M2023-10-31: 5.7M2023-11-15: 6.3M2023-11-30: 5.9M2023-12-15: 5.8M2023-12-29: 5.7M2024-01-12: 5.9M2024-01-31: 6.3M
    the 31 Jan 2024 report24 earlier reportsnormal: 1.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 25 Jan 2024Short interest and volume change

    had 5.9M shares sold short in the 12 Jan 2024 report, 6.9× the same report last year.

    Same report last year: 850K; its normal report is 1.4M.

    See the evidence
    This period
    5.9M (the 12 Jan 2024 report)
    Normal report (median of 24 earlier)
    1.4M
    Typical spread (median absolute deviation)
    353K
    How far from its usual level
    +8.6
    Same report last year
    850K
    History used
    2,205 days
    2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M2023-10-31: 5.7M2023-11-15: 6.3M2023-11-30: 5.9M2023-12-15: 5.8M2023-12-29: 5.7M2024-01-12: 5.9M
    the 12 Jan 2024 report24 earlier reportsnormal: 1.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 11 Jan 2024Short interest and volume change

    had 5.7M shares sold short in the 29 Dec 2023 report, 5.6× the same report last year.

    Same report last year: 1.0M; its normal report is 1.3M.

    See the evidence
    This period
    5.7M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    295K
    How far from its usual level
    +9.9
    Same report last year
    1.0M
    History used
    2,191 days
    2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M2023-10-31: 5.7M2023-11-15: 6.3M2023-11-30: 5.9M2023-12-15: 5.8M2023-12-29: 5.7M
    the 29 Dec 2023 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 28 Dec 2023Short interest and volume change

    had 5.8M shares sold short in the 15 Dec 2023 report, 6.1× the same report last year.

    Same report last year: 950K; its normal report is 1.3M.

    See the evidence
    This period
    5.8M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    1.3M
    Typical spread (median absolute deviation)
    262K
    How far from its usual level
    +11.6
    Same report last year
    950K
    History used
    2,177 days
    2022-12-15: 950K2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M2023-10-31: 5.7M2023-11-15: 6.3M2023-11-30: 5.9M2023-12-15: 5.8M
    the 15 Dec 2023 report24 earlier reportsnormal: 1.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 12 Dec 2023Short interest and volume change

    had 5.9M shares sold short in the 30 Nov 2023 report, 5.8× the same report last year.

    Same report last year: 1.0M; its normal report is 1.2M.

    See the evidence
    This period
    5.9M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    213K
    How far from its usual level
    +14.7
    Same report last year
    1.0M
    History used
    2,162 days
    2022-11-30: 1.0M2022-12-15: 950K2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M2023-10-31: 5.7M2023-11-15: 6.3M2023-11-30: 5.9M
    the 30 Nov 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 28 Nov 2023Short interest and volume change

    had 6.3M shares sold short in the 15 Nov 2023 report, 5.9× the same report last year.

    Same report last year: 1.1M; its normal report is 1.2M.

    See the evidence
    This period
    6.3M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    157K
    How far from its usual level
    +22.0
    Same report last year
    1.1M
    History used
    2,147 days
    2022-11-15: 1.1M2022-11-30: 1.0M2022-12-15: 950K2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M2023-10-31: 5.7M2023-11-15: 6.3M
    the 15 Nov 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 10 Nov 2023Short interest and volume change

    had 5.7M shares sold short in the 31 Oct 2023 report, 4.4× the same report last year.

    Same report last year: 1.3M; its normal report is 1.2M.

    See the evidence
    This period
    5.7M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    155K
    How far from its usual level
    +19.8
    Same report last year
    1.3M
    History used
    2,132 days
    2022-10-31: 1.3M2022-11-15: 1.1M2022-11-30: 1.0M2022-12-15: 950K2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M2023-10-31: 5.7M
    the 31 Oct 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 9 Nov 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 9 Nov 2023Filings record

    Director or officer change

  36. 25 Oct 2023Short interest and volume change

    had 4.8M shares sold short in the 13 Oct 2023 report, 3.9× the same report last year.

    Same report last year: 1.2M; its normal report is 1.2M.

    See the evidence
    This period
    4.8M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    153K
    How far from its usual level
    +16.2
    Same report last year
    1.2M
    History used
    2,114 days
    2022-10-14: 1.2M2022-10-31: 1.3M2022-11-15: 1.1M2022-11-30: 1.0M2022-12-15: 950K2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M2023-10-13: 4.8M
    the 13 Oct 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 12 Oct 2023Short interest and volume change

    had 4.8M shares sold short in the 29 Sep 2023 report, 3.5× the same report last year.

    Same report last year: 1.3M; its normal report is 1.2M.

    See the evidence
    This period
    4.8M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    153K
    How far from its usual level
    +15.8
    Same report last year
    1.3M
    History used
    2,100 days
    2022-09-30: 1.3M2022-10-14: 1.2M2022-10-31: 1.3M2022-11-15: 1.1M2022-11-30: 1.0M2022-12-15: 950K2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M2023-09-29: 4.8M
    the 29 Sep 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 27 Sep 2023Short interest and volume change

    had 3.8M shares sold short in the 15 Sep 2023 report, 2.5× the same report last year.

    Same report last year: 1.5M; its normal report is 1.2M.

    See the evidence
    This period
    3.8M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    153K
    How far from its usual level
    +11.7
    Same report last year
    1.5M
    History used
    2,086 days
    2022-09-15: 1.5M2022-09-30: 1.3M2022-10-14: 1.2M2022-10-31: 1.3M2022-11-15: 1.1M2022-11-30: 1.0M2022-12-15: 950K2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M2023-09-15: 3.8M
    the 15 Sep 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 13 Sep 2023Short interest and volume change

    had 3.2M shares sold short in the 31 Aug 2023 report, 2.5× the same report last year.

    Same report last year: 1.3M; its normal report is 1.2M.

    See the evidence
    This period
    3.2M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    1.2M
    Typical spread (median absolute deviation)
    146K
    How far from its usual level
    +9.2
    Same report last year
    1.3M
    History used
    2,071 days
    2022-08-31: 1.3M2022-09-15: 1.5M2022-09-30: 1.3M2022-10-14: 1.2M2022-10-31: 1.3M2022-11-15: 1.1M2022-11-30: 1.0M2022-12-15: 950K2022-12-30: 1.0M2023-01-13: 850K2023-01-31: 845K2023-02-15: 1.1M2023-02-28: 1.1M2023-03-15: 1.3M2023-03-31: 1.4M2023-04-14: 1.1M2023-04-28: 1.0M2023-05-15: 1.0M2023-05-31: 1.4M2023-06-15: 1.0M2023-06-30: 1.2M2023-07-14: 1.3M2023-07-31: 1.3M2023-08-15: 1.5M2023-08-31: 3.2M
    the 31 Aug 2023 report24 earlier reportsnormal: 1.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 30 Mar 2023Filings record

    Director or officer change

Showing the newest 40 of 75 entries; narrow the window or the kind of data to see older ones.

Not listed: 677 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000943819
Ticker
RMD
Domain
resmed.com
Employer name
ResMed Corp., resmed digital health, resmed motor technologies (3 unverified)
Hq location
CA|SAN DIEGO|92123 (1 unverified)
Lobbying client
resmed
Name
Brightree Home Health & Hospice LLC, Brightree LLC, Brightree Patient Collections LLC, Company and 24 more
Uei
MZYKBT4LPDN9
Wikidata
Q7314903
Wikipedia
ResMed
  • DOL H-1B labor condition applications and PERM certifications506 data points1 Oct 2019 to 14 Sep 2026
  • Federal lobbying disclosures (LDA)13 records, 171 data points1 Jul 1999 to 30 Sep 2026
  • SEC Form 13F institutional holdings4 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)161 records21 Jan 2016 to 19 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1267 data points30 Jun 2008 to 26 Oct 2026
  • SEC Form 4 insider transactions536 records, 1732 data points5 Jan 2016 to 18 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 195 data points1 Oct 2007 to 10 Nov 2022
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026